| abstract |
The present invention relates to new ethers of propenone oximes, a process for their preparation and the pharmaceutical compositions containing them.n n n - Ar et Ar représentent indépendamment un groupe phényle non substitué, mono ou polysubstitué; un radical anthryle-9 ou naphtyle, un groupe pyridyle, thiényle, ou furyle, - R 1 et R 2 désignent indépendamment un atome d'hydrogène, un alkyle en C 1 -C 4 ou avec l'atome d'azote auquel ils sont liés un groupe pyrrolidinyl-1, pipéridino, morpholino ou pipérazinyl-1, -n = 2 ou 3, - M = H, CI, Br ou un groupe alkyle en C 1 -C 6 . The propenone oxime ethers according to the invention correspond to the formula: in which - Ar and Ar independently represent an unsubstituted, mono or polysubstituted phenyl group; an anthryl-9 or naphthyl radical, a pyridyl, thienyl or furyl group, - R 1 and R 2 independently denote a hydrogen atom, a C 1 -C 4 alkyl or with the nitrogen atom to which they are linked a pyrrolidinyl-1, piperidino, morpholino or piperazinyl-1 group, -n = 2 or 3, - M = H, CI, Br or a C 1 -C 6 alkyl group. n n n The invention also relates to the salts of the compounds of formula (1).n n n These compounds have antiplatelet properties and are 5HT 2 receptor antagonists. |